USANA Health Sciences (NYSE:USNA) Rating Lowered to “Strong Sell” at Zacks Research

USANA Health Sciences (NYSE:USNA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

USNA has been the subject of several other research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

USANA Health Sciences Stock Up 3.6%

USNA stock opened at $15.43 on Thursday. USANA Health Sciences has a 52 week low of $14.35 and a 52 week high of $32.32. The firm has a market capitalization of $284.84 million, a P/E ratio of -12.75, a price-to-earnings-growth ratio of 1.63 and a beta of 0.73. The company has a fifty day simple moving average of $20.41 and a two-hundred day simple moving average of $19.66.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). The business had revenue of $223.27 million during the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. As a group, analysts anticipate that USANA Health Sciences will post 0.76 EPS for the current year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, CFO G Doug Iiekking sold 5,360 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total value of $100,500.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Turman Fleming sold 2,450 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director owned 4,230 shares in the company, valued at approximately $75,843.90. The trade was a 36.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,869 shares of company stock worth $261,441 in the last quarter. 0.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue lifted its stake in USANA Health Sciences by 8.5% in the fourth quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company’s stock valued at $130,000 after buying an additional 525 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of USANA Health Sciences by 4.6% during the fourth quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after acquiring an additional 542 shares during the last quarter. Quantbot Technologies LP grew its position in shares of USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after acquiring an additional 646 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of USANA Health Sciences by 13.5% in the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after acquiring an additional 918 shares during the period. Finally, National Bank of Canada FI raised its position in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences News Roundup

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its estimates for Q3 2026 EPS to $0.11 from $0.09, Q1 2027 EPS to $0.34 from $0.31, and Q2 2027 EPS to $0.46 from $0.43. These revisions suggest some improvement in the analyst’s near-term outlook.
• Neutral Sentiment: Wall Street Zen lowered its stock rating on USANA, adding to uncertainty around the company’s outlook. USANA Health Sciences Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: Sidoti’s broader revisions were substantially bearish: FY2026 EPS was cut to $0.76 from $2.12, FY2027 EPS to $1.77 from $2.77, and Q3 2026 EPS to $0.11 from $0.43 in the latest updates. The firm also reduced estimates for Q4 2026, Q1 2027, Q2 2027, and Q3 2027, although some of those forecasts were later partially raised.
• Negative Sentiment: The estimate cuts follow USANA’s latest quarterly results, in which the company reported a $0.07 per-share loss and revenue of $223.27 million, missing analyst expectations of $0.43 EPS and $235 million in revenue. The company’s FY2026 guidance remains just $0.76 EPS, reinforcing concerns about weak profitability and slowing business momentum.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.